ClinicalTrials.gg
Enrolling by invitationNCT06947096Updated Apr 27, 2025

Radiomics-Based AI Model for Predicting Para-Aortic Lymph Node Metastasis in Gastric Cancer Patients

An observational study in Gastric Cancer, Para-Aortic Lymph Node Metastasis and Lymphatic Metastasis, sponsored by Qun Zhao. Enrolling by invitation at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-04-27.

Sponsored by Qun Zhao · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 4 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
120
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,187 studies in Stomach Neoplasms with a site in China — 483 open to participants now, 560 under way, 50 of them phase 3. Stomach Neoplasms · China.

Planned enrollment
224th of 303
120 · median 300
Started
2025
with 116 others
Observational
303 of 1,187
132 open now
Primary completion
2025-06
later than 142 of 559 live
Registered
992nd of 1,187
by date

Among the 1,187 studies in Stomach Neoplasms with a site in China, this one is the 224th largest by planned enrollment of the 303 observational ones that give a count, is one of 117 that started in 2025, is one of 303 observational ones, reaches primary completion later than 142 of the 559 other live ones, and was the 992nd registered.

Stomach Neoplasms

3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

483 of the 1,187 studies in Stomach Neoplasms with a site in China are open now. Recruiting first, the newest first:

478 more — sign in →

All 483 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 27 take children under 18; 70 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,187 studies in Stomach Neoplasms with a site in China, or all of them as a file.
02

Study summary

This study aims to develop and validate an artificial intelligence (AI) model based on radiomics features extracted from preoperative CT images to predict para-aortic lymph node (PALN) metastasis in patients with gastric cancer. Accurately identifying PALN metastasis before surgery can help doctors make better treatment decisions, such as whether to proceed with surgery, consider chemotherapy, or use other treatment strategies. The study will prospectively enroll patients who are diagnosed with gastric cancer and scheduled for surgery. All participants will undergo routine imaging tests, and their data will be analyzed using advanced AI techniques. The results of this study may improve the precision of preoperative staging and support personalized treatment planning for gastric cancer patients.

03

Conditions studied

  • Gastric Cancer
  • Para-Aortic Lymph Node Metastasis
  • Lymphatic Metastasis
  • Preoperative Imaging Assessment
  • Radiomics
  • Artificial Intelligence
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Sampling method
Probability sample

Study population

The study population will consist of adult patients diagnosed with gastric adenocarcinoma who are scheduled to undergo radical gastrectomy at a tertiary care center. All participants will have preoperative contrast-enhanced CT scans and no evidence of distant metastasis. The population represents individuals at risk of para-aortic lymph node metastasis, and is intended to reflect real-world patients who may benefit from non-invasive, AI-assisted preoperative assessment tools. Participants will be enrolled consecutively to minimize selection bias.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults aged 18-80 years.
  2. confirmed gastric adenocarcinoma.
  3. Planned to undergo radical gastrectomy with or without para-aortic lymph node dissection.
  4. Preoperative contrast-enhanced abdominal CT scan available within 3 weeks before surgery.
  5. No evidence of distant on imaging.
  6. performance status 0-2.
  7. Provided written .

Exclusion criteria

Exclusion Criteria:

  1. History of other malignant tumors within the past 5 years.
  2. Received chemotherapy or radiotherapy prior to CT imaging.
  3. Poor-quality or incomplete CT images not suitable for radiomics analysis.
  4. Severe comorbidities that may affect prognosis or surgical decision-making.
  5. Pregnancy or breastfeeding.
  6. Inability to provide or comply with study procedures.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
120 participants (estimated)
Patient registry
No

Interventions

  • Diagnostic testRadiomics-Based AI Imaging Analysis

    This intervention involves the development and application of a radiomics-based artificial intelligence (AI) model to analyze preoperative abdominal CT images of patients with gastric cancer. The AI algorithm extracts high-dimensional imaging features from the para-aortic region to predict the presence or absence of para-aortic lymph node metastasis (PALNM). This non-invasive method aims to assist clinicians in preoperative risk stratification and treatment planning. The model will be trained and validated using manually segmented lymph node regions and correlated with postoperative pathological findings to ensure accuracy and clinical relevance.

06

What researchers measure

Primary outcomes

  1. Diagnostic Accuracy of the AI Radiomics Model for Predicting Para-Aortic Lymph Node Metastasis in Gastric Cancer

    The primary outcome is the diagnostic performance of the radiomics-based AI model in predicting para-aortic lymph node metastasis (PALNM) in patients with gastric cancer. Performance will be evaluated by calculating the area under the receiver operating characteristic curve (AUC), sensitivity, specificity, accuracy, and predictive values. The ground truth for PALNM status will be based on postoperative pathological findings or multidisciplinary consensus diagnosis. The model's predictions will be compared with actual clinical outcomes to assess its reliability and clinical utility.

    Time frame: From Preoperative Imaging to Postoperative Pathological Confirmation (Approximately 4-6 Weeks per Patient)

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Jun 2025, 5 months after the start.

Of 324 non-industry observational studies under Stomach Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 171. This study's planned 5 months is below that.

Counting every sponsor, half of 367 studies reached it within 54 months; a quarter within 29 and three quarters within 119.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2025
First posted
Apr 27, 2025
StartActual
Jan 1, 2025
Primary completionEst.
Jun 30, 2025
CompletionEst.
Jun 30, 2025
Last update
Apr 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06947096
Lead sponsor
Qun Zhao
Collaborators
First Hospital of Shijiazhuang City, Baoding First Central Hospital, Hengshui People's Hospital
Responsible party
Qun Zhao (Professor, Hebei Medical University) — Sponsor-investigator
First posted
Apr 27, 2025
Start date
Jan 1, 2025
Primary completion
Jun 30, 2025 (estimated)
Completion
Jun 30, 2025 (estimated)
Last update
Apr 27, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion